Hiroshima, Japan

Daiki Miki

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Hiroshima Institute of Life Sciences. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Daiki Miki: Innovator in Hepatitis B Research

Introduction

Daiki Miki is a prominent inventor based in Hiroshima, Japan. He has made significant contributions to the field of medical research, particularly in the fight against viral infections. His work focuses on developing innovative solutions to combat hepatitis B virus (HBV) infections.

Latest Patents

Daiki Miki holds a patent for a "Human NTCP-Binding Antibody Capable of Inhibiting Infection of Hepatitis B Virus (HBV) to Human Hepatocytes." This groundbreaking invention aims to provide a new therapeutic approach to prevent HBV from infecting liver cells, which is crucial for improving treatment options for patients.

Career Highlights

Miki is affiliated with the Hiroshima Institute of Life Sciences, where he conducts his research. His dedication to advancing medical science has led to the development of this important patent, showcasing his commitment to addressing public health challenges.

Collaborations

Daiki Miki collaborates with esteemed colleagues, including Michishige Harada and Takehisa Matsumoto. Their combined expertise enhances the research efforts at the Hiroshima Institute of Life Sciences, fostering an environment of innovation and discovery.

Conclusion

Daiki Miki's contributions to hepatitis B research exemplify the impact of innovative thinking in the medical field. His patent represents a significant step forward in the fight against viral infections, highlighting the importance of continued research and collaboration in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…